Protagonist Therapeutics (PTGX) PT Raised to $119 at Barclays following Icotyde approval
Tweet Send to a Friend
Barclays analyst Etzer Darout raised the price target on Protagonist Therapeutics (NASDAQ: PTGX) to $119.00 (from $113.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
